Ascentage Pharma Group International
HKEX:6855

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
HKEX:6855
Watchlist
Price: 41.3 HKD 0.49%
Market Cap: 12.9B HKD
Have any thoughts about
Ascentage Pharma Group International?
Write Note

EV/EBIT
Enterprise Value to EBIT

-36.7
Current
-6.7
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-36.7
=
Enterprise Value
13B HKD
/
EBIT
-329.9m CNY
All Countries
Close
EBIT Growth
CN
Ascentage Pharma Group International
HKEX:6855
Average EV/EBIT: 22.5
Negative Multiple: -36.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 386.8 N/A
US
Abbvie Inc
NYSE:ABBV
23.5
90%
US
Amgen Inc
NASDAQ:AMGN
31.7
90%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
45%
US
Gilead Sciences Inc
NASDAQ:GILD
10
32%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504.8 N/A
AU
CSL Ltd
ASX:CSL
25.5
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
42%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -78.7 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-46.4
2-Years Forward
EV/EBIT
-14.5
3-Years Forward
EV/EBIT
30.3

See Also

Discover More